China Biotech Week in Review: Earnings, Deals and Drug Development [View article]
LTUS (Lotus Pharmaceuticals) reaffirmed 2008 guidance on Friday. That guidance of $13.8M USD in net income is about .29/share fully diluted...making the PE for LTUS well under 4. As far as I can tell, this makes LTUS the best value in the China Biopharma sector today.
WuXi Pharmatech Reports Another Healthy Quarter [View article]
A forward PE of 26? Might want to check out LTUS.OB (Lotus Pharmaceuticals) with a forward PE of UNDER 3 based on 2008 make good of $13.8M net income, or about .29/share.
China Biotech Week in Review: Earnings, Deals and Drug Development [View article]
As far as I can tell, this makes LTUS the best value in the China Biopharma sector today.
WuXi Pharmatech Reports Another Healthy Quarter [View article]